🔗 Share this article Individuals Coming Off Weight-Loss Medications Gain Back Pounds Four Times Faster Compared to Dieters Obesity treatment often requires long-term strategies. A recent study reveals that individuals who come off popular slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who end traditional diet and exercise regimens. Research printed in a prominent medical journal points out that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit. "People using such drugs must be cognizant of the risk of fast rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb. This pace of regain suggests a return to starting mass within about a year and a half. Analyzing Treatments The research, which looked at dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting. Researchers emphasize that individuals who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 0.1 kg a month—post-intervention. Understanding the Rapid Rebound Experts suggest the way of the jabs explains the amplified rebound. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating far more likely." An Ongoing Condition? The NHS recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians contend that, considering the likelihood of weight regain, the therapy should be considered life-long. This opinion is echoed by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," comparing it to managing conditions like diabetes. Patient Accounts People who have come off the medication describe a intense return of cravings. "It felt as if a switch activating and you become starving," said an individual. This difficulty is exacerbated if users have not adopted lasting lifestyle or habit changes during therapy. Significant Adoption Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high. Use is more common among women than men. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private prescriptions rather than the NHS. Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent fix and long-term success likely depends on ongoing behavioural management.
Obesity treatment often requires long-term strategies. A recent study reveals that individuals who come off popular slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass much more quickly than those who end traditional diet and exercise regimens. Research printed in a prominent medical journal points out that while obese people frequently drop a large proportion of their body weight while undergoing treatment, the weight is regained at an estimated rate of 0.8 kg per month once they quit. "People using such drugs must be cognizant of the risk of fast rebound weight gain when the medication concludes," stated lead investigator Dr. Susan Jebb. This pace of regain suggests a return to starting mass within about a year and a half. Analyzing Treatments The research, which looked at dozens of studies involving over 9,000 of participants, compared the results of the injectable medications with conventional dieting. Researchers emphasize that individuals who lose weight through lifestyle changes alone usually experience a slower weight regain—approximately 0.1 kg a month—post-intervention. Understanding the Rapid Rebound Experts suggest the way of the jabs explains the amplified rebound. GLP-1 drugs imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness. "Artificially providing the hormone concentrations several times higher than normal may cause the body to produce less of its endogenous hormone, and could lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist. "Stopping of this GLP-1 'fix' means hunger is unsuppressed, making excessive eating far more likely." An Ongoing Condition? The NHS recommend the jabs for people with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications. A number of clinicians contend that, considering the likelihood of weight regain, the therapy should be considered life-long. This opinion is echoed by pharmaceutical companies, who say that the results "highlight the persistent character of excess weight," comparing it to managing conditions like diabetes. Patient Accounts People who have come off the medication describe a intense return of cravings. "It felt as if a switch activating and you become starving," said an individual. This difficulty is exacerbated if users have not adopted lasting lifestyle or habit changes during therapy. Significant Adoption Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with desire remaining high. Use is more common among women than men. The middle-aged age group shows the greatest usage rates. Many obtain the drugs through private prescriptions rather than the NHS. Ultimately, researchers emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent fix and long-term success likely depends on ongoing behavioural management.